Therapeutic trial of rifabutin after rifampicin-associated dress syndrome in tuberculosis-human immunodeficiency virus coinfected patients

Rannakoe J. Lehloenya; Sipho Dlamini; Rudzani Muloiwa; Betty Kakande; Mzudumile R. Ngwanya; Gail Todd; Keertan Dheda

doi:10.1093/ofid/ofw130

Therapeutic trial of rifabutin after rifampicin-associated dress syndrome in tuberculosis-human immunodeficiency virus coinfected patients

Rannakoe J. Lehloenya
, Sipho Dlamini
, Rudzani Muloiwa
, Betty Kakande
, Mzudumile R. Ngwanya
, Gail Todd
, Keertan Dheda

University of Cape Town

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

Original language	English
Journal	Open Forum Infectious Diseases
Volume	3
Issue number	3
DOIs	https://doi.org/10.1093/ofid/ofw130
Publication status	Published - 1 May 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alternative
Rifabutin
Rifampicin-associated drug eruption
Tuberculosis HIV coinfection

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofw130

Cite this

@article{8aba77024b9545cdbd7b555276ff8e36,

title = "Therapeutic trial of rifabutin after rifampicin-associated dress syndrome in tuberculosis-human immunodeficiency virus coinfected patients",

abstract = "Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.",

keywords = "Alternative, Rifabutin, Rifampicin-associated drug eruption, Tuberculosis HIV coinfection",

author = "Lehloenya, \{Rannakoe J.\} and Sipho Dlamini and Rudzani Muloiwa and Betty Kakande and Ngwanya, \{Mzudumile R.\} and Gail Todd and Keertan Dheda",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = may,

day = "1",

doi = "10.1093/ofid/ofw130",

language = "English",

volume = "3",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Therapeutic trial of rifabutin after rifampicin-associated dress syndrome in tuberculosis-human immunodeficiency virus coinfected patients

AU - Lehloenya, Rannakoe J.

AU - Dlamini, Sipho

AU - Muloiwa, Rudzani

AU - Kakande, Betty

AU - Ngwanya, Mzudumile R.

AU - Todd, Gail

AU - Dheda, Keertan

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

AB - Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

KW - Alternative

KW - Rifabutin

KW - Rifampicin-associated drug eruption

KW - Tuberculosis HIV coinfection

UR - https://www.scopus.com/pages/publications/85015982182

U2 - 10.1093/ofid/ofw130

DO - 10.1093/ofid/ofw130

M3 - Article

AN - SCOPUS:85015982182

SN - 2328-8957

VL - 3

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 3

ER -

Therapeutic trial of rifabutin after rifampicin-associated dress syndrome in tuberculosis-human immunodeficiency virus coinfected patients

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this